Scientific Advisory Board

Robert Doebele, MD, PhD Acting Chief Science Officer and Cofounder

Dr. Robert Doebele co-founded Rain Therapeutics in April 2017. He is Associate Professor of Medicine in the Division of Medical Oncology at the University of Colorado School of Medicine. He is the Director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center co-founded and the principle investigator of the University of Colorado Lung Cancer Specialized Program of Research Excellence. He is also a Senior Editor of the AACR journal Clinical Cancer Research.

Bob received his AB in Molecular Biology from Princeton University, an MD, PhD in Immunology from the University of Pennsylvania. He conducted his internal medicine residency and a medical oncology fellowship at the University of Chicago.

Lori Kunkel, MD

Dr. Lori Kunkel currently serves on the board of directors of Loxo Oncology, Inc., Curis, Inc., Maverick Therapeutics, Inc., and Tocagen, Inc. Previously she has served as acting chief medical officer of Loxo Oncology, Inc., chief medical officer of Pharmacyclics, LLC, and Proteolix, Inc. and vice president of clinical development at Xencor, Inc. Prior to her career in biotechnology, Lori spent a decade in academic medicine as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at University of California, Los Angeles.

Lori has held board certifications in hematology and oncology and holds a BA in biology from the University of California, San Diego and an MD from the University of Southern California.

Christopher Kirk, PhD

Dr. Chris Kirk is co-founder, president, and chief scientific officer of Kezar Life Sciences. Dr. Kirk has worked in the biotechnology industry since 2001 and has held numerous positions in drug discovery and development. Prior to forming Kezar, Chris was the Vice President of Research at Onyx Pharmaceuticals, where he played a key role in the discovery and development of two proteasome inhibitors, carfilzomib (KYPROLIS™) and oprozomib. Chris joined Onyx via the acquisition of Proteolix in 2009, where he was the one of the first scientific hires after their Series A funding.

Chris received his BS from U.C. Davis and his PhD in Cellular and Molecular Biology from the University of Michigan in 1999.

Adam Patterson, PhD

Dr. Adam Patterson is associate professor at the University of Auckland where he has led the translational therapeutics team at the Auckland Cancer Society Research Centre since 2010. Dr. Patterson also leads the Tumour Microenvironment Flagship of the Maurice Wilkins Centre for Molecular Biodiscovery. He has a broad interest in the metabolism of bioreductive prodrugs and their application as antitumour agents, with particular emphasis on selective targeting of the tumor microenvironment.

Dr. Patterson obtained his BA in Biochemistry at the University of Oxford, UK, and his PhD in the field of Bioreductive prodrugs based at the Institute of Molecular Medicine, Oxford and the Medical Research Council Radiobiology Unit, Harwell, UK.

Jeff Smaill, PhD

Dr. Jeff Smaill is an a associate professor at the Auckland Cancer Society Research Centre at the University of Auckland and an associate investigator of the Maurice Wilkins Centre for Molecular Biodiscovery. Dr. Smaill has extensive experience in the design and synthesis of ATP-competitive small molecule kinase inhibitors and is currently interested in developing the next generation of bioreductive prodrugs with a focus on using a hypoxia-activated prodrug strategy to impart increased tumor-selectivity to novel multikinase inhibitors.

Dr. Smaill obtained his BS and PhD degrees in the field of synthetic organic chemistry from the University of Otago in New Zealand.